Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Elizabeth M. Jaffee

Elizabeth M. Jaffee

Department Affiliation: Primary: Oncology; 
Degree: M.D., New York Medical College
Rank: Professor
Telephone Number: 410-955-2957
Fax Number: 410-614-8216
Email Address: ejaffee@jhmi.edu
School of Medicine Address: Room 4M07, Cancer Research Bldg., 1650 Orleans Street, Baltimore, Maryland 21231 

Mechanisms of induction of mouse and human antitumor immune responses

Current projects include:  

  1. The evaluation of mechanisms of immune tolerance to cancer in mouse models of breast and pancreatic cancer.  We have characterized the HER-2/neu transgenic mouse model of spontaneous mammary tumors.  This model demonstrates immune tolerance to the HER-2/neu gene product.  This model is being used to better understand the mechanisms of tolerance to tumor.  In addition, this model is being used to develop vaccine strategies that can overcome this tolerance and induce immunity potent enough to prevent and treat naturally developing tumors.  More recently, we are using a genetic model of pancreatic cancer developed to understand the early inflammatory changes that promote cancer development.
     
  2. The identification of human tumor antigens recognized by T cells.  We are using a novel functional genetic approach developed in our laboratory.  Human tumor specific T cells from vaccinated patients are used to identify immune relevant antigens that are chosen based on an initial genomic screen of overexpressed gene products.  Several candidate targets have been identified and the prevelence of vaccine induced immunity has been assessed .  This rapid screen to identify relevant antigenic targets will allow us to begin to dissect the mechanisms of tumor immunity induction and downregulation at the molecular level in cancer patients.  More recently, we are using proteomics to identify proteins involved in pancreatic cancer development.  We recently identified Annexin A2 as a molecule involved in metastases.
     
  3. The analysis of antitumor immune responses in patients enrolled on vaccine studies.  The focus is on breast and pancreatic cancers.  We are atttempting to identify in vitro correlates of in vivo antitumor immunity induced by vaccine strategies developed in the laboratory and currently under study in the clinics.


Representative Publications:

  • Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol. 2011;186(7):3847-57.  Pub Med Reference
     
  • Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One. 2012;7(2):e31962.  Pub Med Reference
     
  • Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Jr., Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012;18(3):858-68.  Pub Med Reference
     
  • Lutz, E., Yeo, C.J., Lillemoe, K.D., Biedrzycki, B., Kobrin, B., Herman, J., Sugar, E., Piantadosi, S., Cameron, J.L., Solt, S., Onners, B., Tartakovsky, I., Choi, M., Sharma, R., Illei, P.B., Hruban, R.H., Abrams, R.A., Le, D., Jaffee, E., Laheru, D. A lethally irradiated allogeneic granulocyte-macrophange colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a Phase II trial of safety, efficacy, and immune activation. Ann Surg. 253(2):328-35, 2011.  Pub Med Reference
     
  • Zheng, L., Foley, K., Huang, L., Leubner, A., Mo, G., Olino, K., Edil, B.H., Mizuma, M., Sharma, R., Le, D.T., Anders, R.A., Illei, P.B. Van Eyk, J.E., Maitra, A., Laheru, D., Jaffee, E.M.  Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One. 6(4):e19390, 2011.  Pub Med Reference
     
  • Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144(6):1230-40.  Pub Med Reference
     
  • Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Jr., Donehower RC, Jaffee EM, Laheru DA. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. Journal of Immunotherapy. 2013;36(7):382-9.  Pub Med Reference


 


Other graduate programs in which Dr. Jaffee participates:

Cellular and Molecular Medicine Graduate Program
Immunology

 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer